We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Hikma Pharmaceuticals Plc | LSE:HIK | London | Ordinary Share | GB00B0LCW083 | ORD SHS 10P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 13.00 | 0.72% | 1,831.00 | 1,829.00 | 1,831.00 | 1,832.00 | 1,813.00 | 1,825.00 | 85,129 | 12:25:35 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 2.88B | 192M | 0.8685 | 21.08 | 4.05B |
From Apr 2019 to Apr 2024
TIDMHIK
RNS Number : 4388C
Hikma Pharmaceuticals Plc
13 April 2017
Hikma Pharmaceuticals PLC - EIP Awards
LONDON, 13 April 2017: Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: HIK) announces that the Remuneration Committee has made the following conditional awards and nil cost options under the Hikma Pharmaceuticals PLC 2014 Executive Incentive Plan (the "EIP") to Persons Discharging Managerial Responsibility ("PDMR") of the Company.
Awards under the EIP were made on 13 April 2017 at a price of 1,740 pence per Ordinary Share (being the average price for the 30-day period prior to 31 December 2016, in accordance with the EIP rules) as follows:
Notification and public disclosure of transactions by persons discharging managerial responsibilities
Hot Features
Premium
1 Details of the person discharging managerial responsibilities
/ person closely associated
--- --------------------------------------------------------------------------
a) Name Majda Labadi
--- ------------------------ ------------------------------------------------
2 Reason for the notification
--- --------------------------------------------------------------------------
a) Position/status Corporate Vice President for Human Resources
and Head of Operations, MENA
--- ------------------------ ------------------------------------------------
b) Initial notification Initial notification
/Amendment
--- ------------------------ ------------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
--- --------------------------------------------------------------------------
a) Name Hikma Pharmaceuticals PLC
--- ------------------------ ------------------------------------------------
b) LEI 549300BNS685UXH4JI75
--- ------------------------ ------------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
--- --------------------------------------------------------------------------
a) Description of Description: Ordinary shares of 10 pence each
the financial (Shares)
instrument, type ID Code: GB00B0LCW083
of instrument
and identification
code
--- ------------------------ ------------------------------------------------
b) Nature of the The Company granted the named individual above
transaction a conditional award to acquire Shares under
Element B of the 2014 Executive Incentive Plan
(EIP). Shares under Element B EIP award will
vest after 2 years.
--- ------------------------ ------------------------------------------------
c) Price(s) and Price(s): GBP17.40
volume(s) Volume(s): 17,825
--- ------------------------ ------------------------------------------------
d) Aggregated information N/A
--- ------------------------ ------------------------------------------------
e) Date of the transaction 13 April 2017
--- ------------------------ ------------------------------------------------
f) Place of the London Stock Exchange (XLON)
transaction
--- ------------------------ ------------------------------------------------
1 Details of the person discharging managerial responsibilities
/ person closely associated
--- --------------------------------------------------------------------------
a) Name Majda Labadi
--- ------------------------ ------------------------------------------------
2 Reason for the notification
--- --------------------------------------------------------------------------
a) Position/status Corporate Vice President for Human Resources
and Head of Operations, MENA
--- ------------------------ ------------------------------------------------
b) Initial notification Initial notification
/Amendment
--- ------------------------ ------------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
--- --------------------------------------------------------------------------
a) Name Hikma Pharmaceuticals PLC
--- ------------------------ ------------------------------------------------
b) LEI 549300BNS685UXH4JI75
--- ------------------------ ------------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
--- --------------------------------------------------------------------------
a) Description of Description: Ordinary shares of 10 pence each
the financial (Shares)
instrument, type ID Code: GB00B0LCW083
of instrument
and identification
code
--- ------------------------ ------------------------------------------------
b) Nature of the The Company granted the named individual above
transaction a conditional award to acquire Shares under
Element C of the 2014 Executive Incentive Plan
(EIP). Shares under Element C EIP award will
vest after 3 years.
--- ------------------------ ------------------------------------------------
c) Price(s) and Price(s): GBP17.40
volume(s) Volume(s): 16,146
--- ------------------------ ------------------------------------------------
d) Aggregated information N/A
--- ------------------------ ------------------------------------------------
e) Date of the transaction 13 April 2017
--- ------------------------ ------------------------------------------------
f) Place of the London Stock Exchange (XLON)
transaction
--- ------------------------ ------------------------------------------------
1 Details of the person discharging managerial responsibilities
/ person closely associated
--- -----------------------------------------------------------------------------
a) Name Susan Ringdal
--- ------------------------ ---------------------------------------------------
2 Reason for the notification
--- -----------------------------------------------------------------------------
a) Position/status Vice President, Corporate Strategy and Investor
Relations
--- ------------------------ ---------------------------------------------------
b) Initial notification Initial notification
/Amendment
--- ------------------------ ---------------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
--- -----------------------------------------------------------------------------
a) Name Hikma Pharmaceuticals PLC
--- ------------------------ ---------------------------------------------------
b) LEI 549300BNS685UXH4JI75
--- ------------------------ ---------------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
--- -----------------------------------------------------------------------------
a) Description of Description: Ordinary shares of 10 pence each
the financial (Shares)
instrument, type ID Code: GB00B0LCW083
of instrument
and identification
code
--- ------------------------ ---------------------------------------------------
b) Nature of the The Company granted the named individual above
transaction a nil cost option to acquire Shares under Element
B of the 2014 Executive Incentive Plan (EIP).
Shares under Element B EIP award will vest after
2 years.
--- ------------------------ ---------------------------------------------------
c) Price(s) and Price(s): GBP17.40
volume(s) Volume(s): 14,031
--- ------------------------ ---------------------------------------------------
d) Aggregated information N/A
--- ------------------------ ---------------------------------------------------
e) Date of the transaction 13 April 2017
--- ------------------------ ---------------------------------------------------
f) Place of the London Stock Exchange (XLON)
transaction
--- ------------------------ ---------------------------------------------------
1 Details of the person discharging managerial responsibilities
/ person closely associated
--- -----------------------------------------------------------------------------
a) Name Susan Ringdal
--- ------------------------ ---------------------------------------------------
2 Reason for the notification
--- -----------------------------------------------------------------------------
a) Position/status Vice President, Corporate Strategy and Investor
Relations
--- ------------------------ ---------------------------------------------------
b) Initial notification Initial notification
/Amendment
--- ------------------------ ---------------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
--- -----------------------------------------------------------------------------
a) Name Hikma Pharmaceuticals PLC
--- ------------------------ ---------------------------------------------------
b) LEI 549300BNS685UXH4JI75
--- ------------------------ ---------------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
--- -----------------------------------------------------------------------------
a) Description of Description: Ordinary shares of 10 pence each
the financial (Shares)
instrument, type ID Code: GB00B0LCW083
of instrument
and identification
code
--- ------------------------ ---------------------------------------------------
b) Nature of the The Company granted the named individual above
transaction a nil cost option to acquire Shares under Element
C of the 2014 Executive Incentive Plan (EIP).
Shares under Element C EIP award will vest after
3 years.
--- ------------------------ ---------------------------------------------------
c) Price(s) and Price(s): GBP17.40
volume(s) Volume(s): 13,477
--- ------------------------ ---------------------------------------------------
d) Aggregated information N/A
--- ------------------------ ---------------------------------------------------
e) Date of the transaction 13 April 2017
--- ------------------------ ---------------------------------------------------
f) Place of the London Stock Exchange (XLON)
transaction
--- ------------------------ ---------------------------------------------------
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHGRGDSBSBBGRX
(END) Dow Jones Newswires
April 13, 2017 03:43 ET (07:43 GMT)
1 Year Hikma Pharmaceuticals Chart |
1 Month Hikma Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
